Stock Symbol: MOGN

Receive a complete Daily History of this Stock You can receive a complete daily file of this issue since 1970 or stock inception. We will email you the file in ASCII format within a few hours or ordering. Product Details | Order

Business Description
MGI PHARMA, Inc. is an oncology-focused biopharmaceutical company that acquires, develops and commercializes proprietary pharmaceutical products that meet cancer patient needs. The Company's marketed products include Aloxi (palonosetron hydrochloride) injection, Salagen Tablets (pilocarpine hydrochloride) and Hexalen (altretamine) capsules. MGI began promotion of Aloxi (palonosetron hydrochloride) injection, in September 2003, in the United States for the prevention of chemotherapy-induced nausea and vomiting. It markets Salagen Tablets (pilocarpine hydrochloride) in the United States to oncologists as a treatment for the symptoms of radiation-induced dry mouth in head and neck cancer patients and to rheumatologists as a treatment for dry mouth associated with the autoimmune disease Sjogren's syndrome. Hexalen capsules are an orally administered chemotherapeutic agent approved in the United States for treatment of refractory ovarian cancer patients.

Financial Information
For the nine months ended 9/30/04, revenues totaled $130.4 million, up from $37.8 million. Net loss totaled $83.9 million, up from $25 million. Revenues reflect $103.3M in Aloxi injection sales. Higher loss reflects a $83.1 million acquired in-process research and development charge.